Express News Today
Express News Today of market intelligence, Express News Today as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Aortic Valve Market Opportunity Assessment Study
The increasing number of valvular heart disease (VHD) cases, growing efforts to generate awareness about the same among the populace, and favorable medical reimbursement policies are driving the aortic valve market across the globe.
It is being expected that during the forecast period (2018–2023), the market will progress with a CAGR of 10.3%. At this rate, the revenue generated from the sale of such devices would grow from $5.6 billion in 2017 to almost $9.9 billion 0in 2023.
Therefore, as the geriatric population increases across the world, so will the prevalence of VHD, which will continue driving the aortic valve market during the forecast period. Government initiatives being taken to raise the awareness of VHD are also playing an important role in the market growth. For instance, the Alliance for Aging Research, in 2017, designated February 22 as the National Heart Valve Disease Awareness Day in the U.S. The aim behind this was to make people aware of the risk factors and symptoms of the disease for faster detection and treatment.
Request to Get the Sample Pages at:
https://www.psmarketresearch.com/market-analysis/aortic-valve-market/report-sample
Now, among the two types of valves transplanted in the human body — mechanical and tissue/biological — the latter dominated the market during the historical period (2013–2017) in terms of sales volume as well as value. In terms of value, tissue/biological valves held almost 65.0% share in the aortic valve market. Such valves, which are made from tissues of other animals, are quite flexible and can last up to 20 years. Further, people transplanted with biological/tissue valves do not require additional medication.
Therefore, it is clear that the increase in the prevalence of VHD, driven by the growth of the geriatric population, will bode well for the market for aortic valves.
About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Hepatitis Drugs Market is Growing Due to Increasing R&D Investments on Hepatitis Research and Drug Discovery
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
The increasing incidences of various types of hepatitis, such as hepatitis B, and hepatitis C are playing a pivotal role in the growth of the global hepatitis drugs market. According to the Hepatitis B Foundation, a non-profit organization solely dedicated to the global problem of hepatitis B, approximately 400 million people globally were chronically infected with hepatitis B, as reported at the end of September 2015. According to the World Health Organization (WHO), an estimated 130 - 150 million people globally were reported to suffer from hepatitis C, as of July 2015. The increasing incidences of hepatitis have increased the demand of therapeutic drugs for the management of diseases.
Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market/report-sample
However, the high capital expenditure and stringent regulatory requirements are inhibiting the growth of the market. The growing number of collaboration and partnerships is one of the latest trends observed in the market.
Geographically, North America dominated the global market of hepatitis drugs in 2014; whereas the Asian market is expected to witness the fastest growth, with a CAGR of 32.4% during the forecast period.
The key companies operating in the global hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline PLC, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, and Mitsubishi Tanabe Pharma Corporation.
Dermatology Drugs Market Regional Revenue, Trends, Opportunities and Future Prospects
Due to the increasing geriatric population, rising incidents and awareness about dermatological diseases, a strong channel for dermatological drugs, and increasing purchasing power of people, the market for dermatology drugs is growing. An ample number of drugs have been approved by the FDA and other drugs regulatory bodies for various skin conditions and disorders, such as acne, wrinkles, and psoriasis. The dermatology drugs market generated a revenue of $21.5 billion in 2017 and is expected to register a CAGR of 8.2% during the forecast period (2018–2023).
Request to Get the Sample Pages at:
https://www.psmarketresearch.com/market-analysis/dermatology-drug-market/report-sample
The end-users of these drugs include hospitals, clinics, at-home, cosmetic centers, and others, which consists of research and clinical laboratories, ambulatory surgical centers and nursing homes. Among all these, hospitals dominated the dermatology drugs market during the historical period 2013–2017, accounting for 38.0% revenue share in 2017. Moving further to the global ground, North America has the largest market for dermatology drugs. In 2017, the region held a 43.3% share in the market due to high per capita income and growing awareness on newly developed drugs.
Among these, acne is the most common skin disease in the U.S., affecting around 50 million each year. The cost incurred for the treatment of acne in the country was over $1.2 billion in 2013. There are a number of treatments along with dermatology drugs that are available in the market to prevent, manage, and treat dermatological diseases. Hence, the growing incidents of skin diseases is boosting the demand for dermatological drugs, which is further driving the growth of the dermatology drugs market.
Various dermatological drugs manufactured by market players are getting approval from authorized regulatory authorities, such as U.S. Food and Drug Administration and the European Union (EU) that are positively affecting the growth of the dermatology drugs market. For instance, in September 2018, Libtayo (cemiplimab-rwlc) developed by Sanofi received the USFDA approval for treating metastatic cutaneous squamous cell carcinoma in those, who have not qualified for surgical or radiation treatments.
Therefore, it is clear that as more people are affected by dermatological issues in the future, the market for related drugs will also grow.
Biosimilars Market Growth, Demand and Share Assessments for the Regional and Country Level Segments
The market is driven by the rising prevalence of chronic disease, growing investment in research and development by biopharmaceutical organizations, vast pipeline of biosimilars, surging geriatric population, and the cost-efficient nature of biosimilars as compared to approved drugs.
Based on technology, the biosimilars market is classified into monoclonal antibody (mAb), bioassays, nuclear magnetic resonance (NMR), recombinant deoxyribonucleic acid (rDNA), and electrophoresis. Biosimilars manufactured using the mAb technology held 56.0% share in the market in 2018. This technology is further anticipated to be the fastest growing due to its large-scale deployment in the development of therapeutics to treat various diseases, such as immunological, cancer, and infections.
Request to Get the Sample Pages at:
https://www.psmarketresearch.com/market-analysis/biosimilars-market/report-sample
On a global ground, in 2018, Europe dominated the biosimilars market with nearly 47.7% share. This is ascribed to the flexible regulatory parameters, surging aging population, and increasing R&D investments by biopharmaceutical organizations in the region.
Companies in North America have more freedom to price their products as they want compared to other regions, and advanced technologies and trained scientific personnel are readily available in here, which make it ideal for pharmaceutical companies.
Access Detailed Report Summary:
https://www.psmarketresearch.com/market-analysis/biosimilars-market
According to the Population Reference Bureau report, titled Aging in the United States, the aging population is anticipated to double by 2060, resulting in the need for old age-related disease management. Furthermore, according to the Centers for Disease Control and Prevention (CDC), around 60.0% of the adults in the U.S. are suffering from one or more chronic diseases.
Furthermore, in January 2019, Samsung Bioepis Co. Ltd. partnered with 3SBio Group to expand the business of biosimilars in China. With the collaboration, Samsung Bioepis Co. Ltd. will seek to enlarge its biosimilars portfolio, while 3SBio Group will be supported by the sales of Avastin.
Some of the key players operating in the market, globally, are Samsung Bioepis Co. Ltd., AMEGA Biotech, Synthon Holding B.V., Coherus BioSciences Inc., Celltrion Inc., BIOCAD, Zydus Cadila, Teva Pharmaceutical Industries Limited, Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., and Mylan N.V.
Biopharmaceuticals Market Segmental Analysis by Therapeutics, Diagnostics, Patent, Drugs Policy and Regulatory Landscape
The global biopharmaceuticals market is increasing, due to growing aging population. In addition, the increasing healthcare investments around the world are propelling the increase in R&D investments, which is fuelling the growth of the global biopharmaceuticals market. Furthermore, the increasing prevalence of chronic diseases due to unhealthy lifestyle, poor diet, excess alcohol consumption, and lack of physical activity is also contributing to the growth in demand of biopharmaceuticals globally.
On the basis of types, the global recombinant human insulin market segment is expected to witness fastest growth during the forecast period. Among the application segment, the oncology segment accounted for the largest market in the global biopharmaceuticals market in 2014; and is expected to witness fastest growth, with 11.1% CAGR during the period 2015 – 2020.
Download Sample of This Research Report:
https://www.psmarketresearch.com/market-analysis/biopharmaceuticals-market/report-sample
However, the high cost and side effects of biopharmaceuticals is a key restraint, which is adversely impacting the growth of the global biopharmaceuticals market. In addition, the entry of low cost biosimilars of existing biopharmaceuticals, also acts as a restraint in the growth of the global biopharmaceuticals market. The Asian biopharmaceuticals market is expected to witness fastest growth, with a CAGR of 10.6% during the period 2015 – 2020.
The key companies operating in the global biopharmaceuticals market include AbbVie Inc, Sanofi, Eli Lilly and Company, Pfizer Inc., Abbott Laboratories, AstraZeneca PLC, Novartis AG, Biogen Idec , Bristol-Myers Squibb Company and Amgen Inc.
BIOPHARMACEUTICALS MARKET SEGMENTATION
Global Biopharmaceuticals market breakdown by type
- Monoclonal Antibodies Market
- Recombinant Proteins Market
- Interferon Market
- Colony-Stimulating Factor Market
- Erythropoietin Market
- Recombinant Human Insulin Market
- Vaccines Market
- Growth Hormones Market
- Purified Proteins Market
- Others Market
Global Biopharmaceuticals market breakdown by application
- Oncology Market
- Inflammatory and Infectious Diseases Market
- Metabolic Disorders Market
- Neurological Disorders Market
- Cardiovascular Diseases Market
- Others Market
Global Biopharmaceuticals market breakdown by geography
- North America – The U.S, Canada, and Rest of North America
- Europe – Germany, The U.K., France, Russia, Italy, Spain, and Rest of Europe
- Asia – India, China, Japan, and Rest of Asia.
- Rest of the World (RoW) –Brazil, Australia, and others
 Market Forward)
Rising Disease Prevalence to Drive Age-Related Macular Degeneration (AMD) Market Forward
Registering a CAGR of 7.6% during the forecast period (2016–2022), the global age-related macular degeneration (AMD) market is projected to garner $8.9 billion by 2022, significantly growing from $5.3 billion in 2015.
The market is experiencing growth due to the rising geriatric population, growing pipeline for AMD therapeutics, surging chronic disease prevalence, and increasing healthcare expenditure. Age-related macular degeneration is a retinal disorder, which is indicated by changes in the fundus of the eye. It commonly affects the elderly, in which, first, the central vision becomes blurred, which ultimately leads to blindness.
The age-related macular degeneration market is classified into Asia-Pacific, Europe, North America, and Rest of the World, based on region. In 2015, the highest value share in the market was held by the North American region. This was attributed to the rising prevalence of conditions, such as obesity and hypertension. Further, the presence of major pharmaceutical companies supports the regional market growth. In 2022, with high healthcare expenditure of countries in the region, it is predicted to hold more than 90.0% of the market share.
Download Report Sample at:
The AMD market is witnessing the trend of the rising awareness about the disease. Various activities, campaigns, and programs are being conducted by NGOs, healthcare providers, and optometrists’ associations to sensitize people about the disease and its course of treatment. February is celebrated as the National AMD awareness month as a measure to encourage people to educate themselves about the disease and understand the risk factors and be aware in case they exhibit any of the symptoms. The awareness about the disease has also resulted in increased funding for research related to the AMD.
Therefore, the market for AMD is predicted to register remarkable growth in the forecast period with the rising prevalence of this disease and surging geriatric population.
About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Active Implantable Medical Devices Market Share Analysis of The Top Industry Players, Growth Opportunities
The active implantable medical devices market is projected to generate a revenue of $28,878.6 million in 2023, advancing at an 8.0% CAGR during the forecast period (2017–2023). The market is growing due to the surging aging population, rising prevalence of cardiovascular diseases and neurological disorders, increasing research & development activities, and technological advancements. Active implantable medical devices are devices that are intended to be partially or totally introduced, medically or surgically, into the human body, or by medical intervention into a natural orifice, and which are meant to remain inside after the procedure.
When product is taken into consideration, the active implantable medical devices market is categorized into neurostimulator, implantable heart monitor/insertable loop recorder (IHM/ILR), implantable cardioverter defibrillator (ICD), ventricular assist device (VAD), implantable cardiac pacemaker (ICP), and implantable hearing devices (IHD). Out of these, the ICD category dominated the market during the historical period (2013–2016) and is further predicted to account for the major share of the market during the forecast period. The category is further bifurcated into subcutaneous ICD and transvenous ICD, between which, transvenous ICD held the largest of the market in 2016.
Request to Get the Sample Pages at:
Among all the regions, namely North America, Asia-Pacific (APAC), Europe, Middle East & Africa (MEA), and Latin America (LATAM), North America accounted for the major share of the active implantable medical devices market during the historical period and is predicted to dominate the market during the forecast period as well. This is attributed to the rising prevalence of cardiovascular diseases and neurological disorders and steadily increasing geriatric population. The APAC region is expected to witness the fastest growth during the forecast period.
Access Report Description at:
https://www.psmarketresearch.com/market-analysis/active-implantable-medical-devices-market
The development of technologically advanced active implantable devices is another factor which is driving the active implantable medical devices market. Technological advancements in ICDs have revolutionized cardiovascular surgeries. Some of the recent developments in ICDs include extended battery life, development of magnetic resonance imaging compatible ICDs, and quadripolar lead devices. In addition to this, the adoption of biomaterials is also an important development in the domain, as it has led to high success rate of active implants. Advanced biomaterials are easy to fabricate, resilient, and highly strong and biocompatible inert.
Hence, the market is registering growth due to technological advancements and the rising prevalence of neurological disorders and cardiovascular diseases.
active implantable medical devices market
active implantable medical devices market share
active implantable medical devices market size
active implantable medical devices market demand
